TempraMed Enters Israeli Pharmacy Network with First Commercial Order

TempraMed Technologies Ltd. ( (TSE:VIVI) ) has shared an update.

TempraMed Technologies has received its first commercial order in Israel and completed an initial shipment to the warehouse of Guri A.A.O., one of the country’s leading medical and retail distributors, marking its entry into Israel’s national pharmacy network. The deal shifts TempraMed beyond its direct-to-consumer model into a scaled B2B strategy, leveraging Guri’s extensive relationships with 2,500 supermarkets, pharmacy chains, HMOs, and independent pharmacies to expand availability of its temperature-protection products across a sophisticated healthcare market with high use of injectable and other temperature-sensitive therapies, bolstering the company’s global expansion and in-store presence.

More about TempraMed Technologies Ltd.

TempraMed Technologies Ltd. is a global medical-technology company specializing in innovative, temperature-controlled medication storage solutions. Its patented, FDA-registered devices, including VIVI Cap and VIVI Epi, use space-grade thermal insulation to protect temperature-sensitive medications without batteries or external power, targeting patients and healthcare providers who need reliable medication management in North America, Europe, Asia, and other international markets.

Average Trading Volume: 42,914

For an in-depth examination of VIVI stock, go to TipRanks’ Overview page.